

Table 8: Analysis of NIHSS Score and Change From Baseline Using a Repeated Measures Mixed Effects Model in the Modified Intent-to-Treat (MITT) Population

Analysis of NIHSS score and change from baseline using a repeated measures mixed effects model in the Modified-Intent-to-Treat (MITT) population

| | Adjusted mean change from baseline (Natalizumab vs placebo) | Two-sided 90% confidence interval | One sided p-value |
|------------------|---|---|-------------------------|
| 24 Hours | -0.25 | [-2.48, 1.98] | 0.427 |
| Day 5 | 1.71 | [-0.52, 3.94] | 0.896 |
| Day 30 | 3.15 | [0.89, 5.40] | 0.989 |
| Day 90/Final Vst | 1.93 | [-0.38, 4.25] | 0.915 |

Note 1: The MITT population is defined as all subjects who were randomized and have received the entire infusion of study treatment.

2: The repeated measures mixed effects model is modeling absolute change in NIHSS score relative to baseline and using an autoregressive variance-covariance matrix. The model adjusts for treatment, time, treatment by time, log baseline DWI volume, treatment time window, tPA use, baseline NIHSS score and location of stroke.